Table 1 Characteristics of HIV patients enrolled at Carmelo Hospital of Chókwè of between January 1, 2002 and December 31, 2019 by Outcome Status.
N = 16,321 | Total | Retention | Attrition | |||||
|---|---|---|---|---|---|---|---|---|
Death | LTFU | |||||||
N | % | N | % | N | % | N | % | |
Gender | ||||||||
Male | 6664 | 40.80% | 2361 | 32.40% | 1448 | 52.2% | 2023 | 49.0% |
Female | 9657 | 59.20% | 4918 | 67.60% | 1328 | 47.8% | 2108 | 51.0% |
Age (years) , median (IQR) | 35 | (15–93) | 36 | (15–84) | 36 | (15–93) | 33 | (15–82) |
Age band | ||||||||
15–24 | 1697 | 10.40% | 628 | 8.60% | 208 | 7.5% | 586 | 14.2% |
25–34 | 6190 | 37.90% | 2618 | 36.00% | 982 | 35.4% | 1755 | 42.5% |
35–44 | 4713 | 28.90% | 2285 | 31.40% | 786 | 28.3% | 1085 | 26.3% |
45–54 | 2490 | 15.30% | 1216 | 16.70% | 515 | 18.6% | 447 | 10.8% |
55 + | 1231 | 7.50% | 532 | 7.30% | 285 | 10.3% | 258 | 6.2% |
Point of entry | ||||||||
In-patient | 2431 | 14.90% | 315 | 4.30% | 1578 | 56.8% | 346 | 8.4% |
Out-patient | 13,890 | 85.10% | 6964 | 95.70% | 1198 | 43.2% | 3785 | 91.6% |
CD4 + T-cell count (Cell/µL) , median (IQR) | 192 | (0–2895) | 256 | (1–2895) | 67 | (0–1763) | 197 | (0–2802) |
CD4 + T-cell count (Cell/µL) Range | ||||||||
< 50 | 2713 | 16.6% | 593 | 8.1% | 1220 | 43.9% | 597 | 14.5% |
50–99 | 2858 | 17.5% | 1173 | 16.1% | 594 | 21.4% | 676 | 16.4% |
100–199 | 2804 | 17.2% | 1135 | 15.6% | 451 | 16.2% | 821 | 19.9% |
200–349 | 4665 | 28.6% | 2299 | 31.6% | 399 | 14.4% | 1330 | 32.2% |
350–499 | 1356 | 8.3% | 737 | 10.1% | 62 | 2.2% | 414 | 10.0% |
500 + | 1925 | 11.8% | 1342 | 18.4% | 50 | 1.8% | 293 | 7.1% |
Previous ART exposition | ||||||||
ART naive | 15,454 | 94.70% | 6944 | 95.40% | 2627 | 94.6% | 3843 | 93.0% |
ART non-naive | 867 | 5.30% | 335 | 4.60% | 149 | 5.4% | 288 | 7.0% |
Previous Anti-TB Treatment (ATT) | ||||||||
Complete ATT before ART initiation | 511 | 3.10% | 224 | 3.10% | 54 | 2.5% | 152 | 3.7% |
Initiated ATT < 90 days after ART initiation | 4667 | 28.60% | 1061 | 14.60% | 2072 | 97.4% | 1040 | 25.2% |
Unexposed to ATT initiation | 10,490 | 64.30% | 5994 | 82.30% | 1 | 0.0% | 2937 | 71.1% |
WHO clinical staging of HIV disease | ||||||||
Clinical stage I | 4501 | 27.60% | 2787 | 38.30% | 75 | 2.7% | 1066 | 25.8% |
Clinical stage II | 3588 | 22.00% | 1990 | 27.30% | 119 | 4.3% | 970 | 23.5% |
Clinical stage III | 2737 | 16.80% | 1235 | 17.00% | 165 | 5.9% | 870 | 21.1% |
Clinical stage IV | 5495 | 33.70% | 1267 | 17.40% | 2417 | 87.1% | 1225 | 29.7% |
Kaposi Sarcoma | ||||||||
Kaposi Sarcoma | 299 | 1.80% | 54 | 0.70% | 133 | 4.8% | 80 | 1.9% |
No Kaposi Sarcoma | 16,022 | 98.20% | 7225 | 99.30% | 2643 | 95.2% | 4051 | 98.1% |
ART enrollment year | ||||||||
2002 | 8 | 0.00% | 2 | 0.00% | 4 | 0.1% | 0 | 0.0% |
2003 | 77 | 0.50% | 42 | 0.60% | 18 | 0.6% | 6 | 0.1% |
2004 | 63 | 0.40% | 29 | 0.40% | 21 | 0.8% | 6 | 0.1% |
2005 | 234 | 1.40% | 94 | 1.30% | 80 | 2.9% | 25 | 0.6% |
2006 | 785 | 4.80% | 293 | 4.00% | 239 | 8.6% | 147 | 3.6% |
2007 | 1232 | 7.50% | 439 | 6.00% | 348 | 12.5% | 295 | 7.1% |
2008 | 1282 | 7.90% | 526 | 7.20% | 284 | 10.2% | 286 | 6.9% |
2009 | 1273 | 7.80% | 538 | 7.40% | 277 | 10.0% | 287 | 6.9% |
2010 | 1469 | 9.00% | 528 | 7.30% | 285 | 10.3% | 425 | 10.3% |
2011 | 1205 | 7.40% | 437 | 6.00% | 237 | 8.5% | 359 | 8.7% |
2012 | 1398 | 8.60% | 565 | 7.80% | 207 | 7.5% | 442 | 10.7% |
2013 | 1030 | 6.30% | 477 | 6.60% | 101 | 3.6% | 342 | 8.3% |
2014 | 1732 | 10.60% | 828 | 11.40% | 194 | 7.0% | 497 | 12.0% |
2015 | 1415 | 8.70% | 698 | 9.60% | 152 | 5.5% | 386 | 9.3% |
2016 | 1164 | 7.10% | 612 | 8.40% | 140 | 5.0% | 271 | 6.6% |
2017 | 844 | 5.20% | 431 | 5.90% | 111 | 4.0% | 194 | 4.7% |
2018 | 674 | 4.10% | 396 | 5.40% | 65 | 2.3% | 123 | 3.0% |
2019 | 436 | 2.70% | 344 | 4.70% | 13 | 0.5% | 40 | 1.0% |
ART therapy initiation | ||||||||
ABC + 3TC + EFV | 56 | 0.30% | 19 | 0.30% | 25 | 0.9% | 5 | 0.1% |
ABC + 3TC + LPV/RTV | 16 | 0.10% | 4 | 0.10% | 7 | 0.3% | 4 | 0.1% |
AZT + 3TC + ABC | 203 | 1.20% | 67 | 0.90% | 48 | 1.7% | 61 | 1.5% |
AZT + 3TC + EFV | 418 | 2.60% | 190 | 2.60% | 80 | 2.9% | 114 | 2.8% |
AZT + 3TC + LPV/RTV | 52 | 0.30% | 30 | 0.40% | 8 | 0.3% | 11 | 0.3% |
AZT + 3TC + NVP | 5511 | 33.80% | 2750 | 37.80% | 600 | 21.6% | 1360 | 32.9% |
D4T + 3TC + ABC | 531 | 3.30% | 70 | 1.00% | 263 | 9.5% | 143 | 3.5% |
D4T + 3TC + EFV | 666 | 4.10% | 43 | 0.60% | 344 | 12.4% | 212 | 5.1% |
D4T + 3TC + LPV/RTV | 3 | 0.00% | 1 | 0.00% | 1 | 0.0% | 1 | 0.0% |
D4T + 3TC + NVP | 1588 | 9.70% | 138 | 1.90% | 638 | 23.0% | 531 | 12.9% |
TDF + 3TC + DTG | 68 | 0.40% | 65 | 0.90% | 0 | 0.0% | 1 | 0.0% |
TDF + 3TC + EFV | 6767 | 41.50% | 3631 | 49.90% | 690 | 24.9% | 1615 | 39.1% |
TDF + 3TC + LPV/RTV | 442 | 2.70% | 271 | 3.70% | 72 | 2.6% | 73 | 1.8% |
